Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Have you signed up to access the PPE portal?
Last month the Department of Health and Social Care (DHSC) announced that community pharmacies could now order additional personal protective equipment (PPE) through the online portal in an emergency. By now, community pharmacies should have received an email invitation to their shared NHSmail inbox to register to access the portal. If they have not responded...
SMR guidance includes referrals to New Medicine Service
New NHS guidance for Primary Care Networks (PCNs) on the provision of Structured Medication Reviews (SMR) includes referrals being made to the community pharmacy New Medicine Service. The guidance has been published by NHS England and NHS Improvement to support PCN clinical pharmacy teams with implementation of the structured medication review and optimisation service requirements...
CPCF Health Campaigns agreed for 2020/21
Each year, pharmacies are required to participate in up to six public health campaigns at the request of NHS England and NHS Improvement (NHSE&I). The topics of these campaigns are agreed by NHSE&I and PSNC. At the start of 2020/21 we agreed that the campaigns would be suspended due to the COVID-19 pandemic. We have...
Boxing Day 2020 Opening Hours
Contractors are reminded that this year Boxing Day (26 December 2020) is a Saturday, a normal day for the purposes of community pharmacy opening hours. Therefore, pharmacies must open on the 26th for any core and supplementary hours. The substitute bank holiday for Boxing Day this year is Monday 28 December, when contractors do not...
Test and Trace – disagreeing with assessments and escalating the case
Contractors are reminded that if they disagree with an assessment or an identification of a recent close contact by an NHS Test and Trace contact tracer, they should ask to speak to his or her supervisor, so that the case can be escalated and reviewed. NHS Test and Trace aims to help trace recent close contacts of...
September 2020 Price Concessions – 1st Update
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price Concession Alendronic acid 10mg tablets 28 £5.79 Amiodarone 200mg tablets 28 £2.30 Clonidine 25microgram tablets 112 £14.20 Donepezil 10mg tablets 28 £1.90 Duloxetine 20mg gastro-resistant capsules 28 £8.71 Enalapril 10mg tablets 28 £3.91 Enalapril...
Are you dispensing incorrectly written prescriptions for specials?
In the last few months PSNC has received several reports from pharmacy contractors who have incurred significant losses from dispensing unlicensed medicinal products (specials) because prescriptions have not been issued/written correctly by the prescriber. Where prescribing of a specials product is considered appropriate by the prescriber, a prescription must be issued with the correct product...
New specials products added to dm+d
Following representations made by PSNC, a total of 24 new unlicensed products (see table below) have been added to NHS dictionary of medicines and devices (dm+d) as ‘(Special Order)’ or ‘(Imported (Country))’ listings. Due to ongoing supply issues affecting the availability of certain licensed products and following recommendations for prescribers to consider the prescribing of...
Shortage Notice: Cloral betaine 707mg tablets
The manufacturer Marlborough Pharmaceuticals has advised that Cloral betaine 707mg tablets are out of stock with resupply expected November 2020. In the interim, supply of an alternative imported unlicensed medicinal product (specials) is available through Alliance Healthcare Specials using PIP code: 802-0745. A prescription for a pack of 30 x Cloral betaine 707mg tablets submitted...
27 products on dm+d reclassified as specials
Following checks carried out by PSNC, 27 products (see table below) listed on the NHS dictionary of medicines and devices (dm+d) have been updated to reflect their unlicensed status. This means that the respective product entries have been annotated with either ‘(Special Order)’ or ‘(Imported (Country))’ against their Actual Medicinal Product (AMP) names. The new annotation ensures that...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
Keytruda/Lenvima combo shows promise in hard-to-treat cancers
Data shows a range of responses in different tumours
University of Edinburgh spinout Cellinta will develop gene therapies for cancer
Investors include SV Health Investors and Cancer Research UK
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer
Detailed results presented at ESMO also show benefit in prostate cancer
CHMP backs seven new meds in September meeting
Positive opinions include Pacira's Exparel and two new vaccines from Sanofi
BMS' Opdivo wins new NICE lung cancer backing
The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers
Tumour agnostic therapy demonstrates sustained efficacy
Access to coronavirus tests should be ‘top priority’, says NHS Confederation director
Concerns over NHS Test and Trace system exacerbated by continuing rise in cases
NICE u-turn sees Akcea's Waylivra win NHS funding
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Shine bright in 2020!
The deadline for entering the 2020 PharmaTimes Communications Awards, Sales Awards and Marketer of the Year competitions has been extended to Friday October 2 after a last-minute spike in enquiries
IVD industry must be supported in COVID-19 recovery strategy, says BIVDA
Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
Over half of patients treated with combination therapy were alive and relapse-free after five years
AZ picks up oral PCSK9 inhibitor programme from Dogma
AZ will take the programme forward into clinical development
Lilly’s COVID-19 antibody shows promise in mid-stage study
Middle dose tested hit the primary endpoint of the Phase II trial
Sleep apnoea linked to poorer outcomes from COVID-19, study finds
People with sleep condition could be at an increased risk of adverse outcomes from COVID-19
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/